{
  "meta": {
    "title": "26_Hpa_Axis_Drugs_Acting_On_Bone_Osteoporosis",
    "url": "https://brainandscalpel.vercel.app/26-hpa-axis-drugs-acting-on-bone-osteoporosis-36c29bfe.html",
    "scrapedAt": "2025-11-30T06:59:50.840Z"
  },
  "questions": [
    {
      "id": 54432,
      "choices": [
        {
          "id": 229582,
          "text": "Increase adult stature"
        },
        {
          "id": 229583,
          "text": "Cause hypertrophy of penis"
        },
        {
          "id": 229584,
          "text": "Have no effect on adult stature"
        },
        {
          "id": 229585,
          "text": "Reduce adult statue"
        }
      ],
      "text": "An endocrinologist decided to give a 7-year-old boy testosterone therapy and continued it till puberty. The therapy is likely to",
      "unique_key": "Q7125131",
      "question_audio": null,
      "question_video": null,
      "map_id": 34380139,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Reduce adult stature. Testosterone therapy in a prepubertal boy leads to early epiphyseal plate closure, which results in reduced adult height. Initially, testosterone stimulates linear growth by promoting IGF-1 (insulin-like growth factor-1) secretion from the liver. However, with prolonged therapy, testosterone is converted to estradiol via aromatase, which accelerates epiphyseal fusion. Since bone growth stops once the growth plates close, early exposure to high testosterone levels shortens the growth phase, ultimately reducing final adult height. This effect is particularly significant when testosterone is administered before the natural pubertal surge. Incorrect Options: A. Increase adult stature: While testosterone initially stimulates growth, the premature epiphyseal plate closure caused by its conversion to estrogen ultimately reduces the final height rather than increasing it. B. Cause hypertrophy of the penis: Testosterone does promote penile growth when given after the onset of puberty or in conditions like delayed puberty. However, in a 7-year-old boy, the prepubertal state means that the effect on penile growth would be limited, as DHT (dihydrotestosterone)-mediated genital development occurs later during puberty. C. Have no effect on adult stature: This is incorrect because testosterone has a definitive impact on bone growth and final height. The early administration of testosterone initially increases growth rate but later reduces final height due to early epiphyseal closure.",
      "correct_choice_id": 229585,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/34290871700145009/34290871700145009.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/34290871700145009/34290871700145009.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54433,
      "choices": [
        {
          "id": 229586,
          "text": "Erosive esophagitis"
        },
        {
          "id": 229587,
          "text": "Constipation"
        },
        {
          "id": 229588,
          "text": "Cholelithiasis"
        },
        {
          "id": 229589,
          "text": "Osteonecrosis"
        }
      ],
      "text": "A patient Geeta began taking alendronate and she was advised to large amount of water and remain in the standing position for at least half an hour till she had the first meal of the day. These instructions were given to reduce the risk of",
      "unique_key": "Q2770135",
      "question_audio": null,
      "question_video": null,
      "map_id": 34510577,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Erosive esophagitis. Alendronate is a bisphosphonate used to treat osteoporosis by inhibiting osteoclast-mediated bone resorption. However, it is highly irritating to the esophageal mucosa, and if not taken properly, it can cause erosive esophagitis, ulcers, and severe esophageal irritation. To minimize this risk, patients are instructed to take alendronate with a full glass of water and remain upright for at least 30 minutes to prevent the drug from lingering in the esophagus. This allows the medication to pass quickly into the stomach, reducing the risk of esophageal injury. Incorrect Options: B. Constipation: Bisphosphonates like alendronate are not commonly associated with constipation. Instead, gastrointestinal side effects such as acid reflux, nausea, and abdominal pain are more frequent. C. Cholelithiasis (Gallstones): Alendronate has no known association with gallstone formation. Cholelithiasis is more commonly linked to hormonal factors, obesity, rapid weight loss, and high-fat diets, rather than bisphosphonate use. D. Osteonecrosis: Osteonecrosis of the jaw (ONJ) is a rare but serious adverse effect of long-term bisphosphonate therapy, especially in patients receiving high doses for cancer-related bone disease. However, the given instructions (taking with water and remaining upright) are meant to prevent esophagitis, not osteonecrosis. ONJ prevention primarily involves good oral hygiene and avoiding invasive dental procedures while on bisphosphonates.",
      "correct_choice_id": 229586,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/14192471700145040/14192471700145040.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/14192471700145040/14192471700145040.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54434,
      "choices": [
        {
          "id": 229590,
          "text": "Thyroxine"
        },
        {
          "id": 229591,
          "text": "Teriparatide"
        },
        {
          "id": 229592,
          "text": "Calcium"
        },
        {
          "id": 229593,
          "text": "Alendronate"
        }
      ],
      "text": "All of these drugs can be used in the treatment of post-menopausal osteoporosis EXCEPT",
      "unique_key": "Q3953199",
      "question_audio": null,
      "question_video": null,
      "map_id": 34097879,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Thyroxine. Thyroxine (levothyroxine) is not used in the treatment of postmenopausal osteoporosis and may even worsen bone loss if given in excess. High levels of thyroxine (as seen in hyperthyroidism or over-replacement therapy in hypothyroid patients) increase bone turnover, leading to enhanced osteoclast activity and accelerated bone resorption. This results in decreased bone mineral density (BMD), predisposing postmenopausal women to fractures. Therefore, thyroxine is not an appropriate treatment for osteoporosis and can actually exacerbate it. Incorrect Options: B. Teriparatide: Teriparatide is a recombinant parathyroid hormone (PTH) analog that stimulates bone formation by increasing osteoblast activity. It is used for severe osteoporosis in postmenopausal women at high risk of fractures. Unlike other osteoporosis treatments that primarily prevent bone loss, teriparatide actively promotes new bone formation, making it an effective therapy. C. Calcium: Calcium supplementation is essential for bone health and osteoporosis management. Adequate calcium intake (along with vitamin D) helps maintain bone mineral density and reduces the risk of fractures. Calcium is often prescribed as part of a comprehensive osteoporosis treatment plan. D. Alendronate: Alendronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption, helping to preserve bone density and prevent fractures. It is a first-line drug for postmenopausal osteoporosis and is widely used to reduce the risk of vertebral and hip fractures.",
      "correct_choice_id": 229590,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/7315421700145054/7315421700145054.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/7315421700145054/7315421700145054.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54435,
      "choices": [
        {
          "id": 229594,
          "text": "Calcitriol"
        },
        {
          "id": 229595,
          "text": "Cholecalciferol"
        },
        {
          "id": 229596,
          "text": "Calcifediol"
        },
        {
          "id": 229597,
          "text": "Calciferol"
        }
      ],
      "text": "A child Mahesh has been diagnosed to be having vitamin D dependent rickets. The most appropriate vitamin D preparation for Mm is",
      "unique_key": "Q8968154",
      "question_audio": null,
      "question_video": null,
      "map_id": 34391274,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Calcitriol. Vitamin D-dependent rickets (VDDR) is a rare genetic disorder caused by defects in vitamin D metabolism, leading to inadequate bone mineralization and rickets. There are two types: VDDR Type 1 (VDDR1A): Caused by a defect in 1α-hydroxylase, the enzyme responsible for converting calcifediol (25-hydroxyvitamin D) into calcitriol (1,25-dihydroxyvitamin D). VDDR Type 2 (VDDR2A): Due to mutations in the vitamin D receptor (VDR), causing resistance to calcitriol. Since patients with VDDR Type 1 cannot convert calcifediol to calcitriol, the most appropriate treatment is direct administration of calcitriol, which bypasses the enzyme deficiency and helps normalize calcium and phosphate homeostasis. Calcitriol is the active form of vitamin D and works immediately without requiring further activation. Incorrect Options: B. Cholecalciferol (Vitamin D3): Cholecalciferol requires two-step activation: first, conversion to calcifediol in the liver, and then to calcitriol in the kidneys. Since patients with VDDR1A lack the necessary enzyme (1α-hydroxylase) to complete this process, cholecalciferol is ineffective in treating this condition. C. Calcifediol (25-hydroxyvitamin D3): While calcifediol is the intermediate form of vitamin D, it still requires conversion to calcitriol by 1α-hydroxylase in the kidneys. Since this enzyme is deficient in VDDR1A, calcifediol is not useful as it cannot be converted into its active form. D. Calciferol (Vitamin D2/Ergocalciferol): Like cholecalciferol, ergocalciferol (Vitamin D2) also requires hepatic and renal activation before becoming biologically active. Because VDDR1A patients cannot convert it to its active form (calcitriol), it is ineffective in this condition.",
      "correct_choice_id": 229594,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/14230131700145094/14230131700145094.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/14230131700145094/14230131700145094.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54436,
      "choices": [
        {
          "id": 229598,
          "text": "Prednisone"
        },
        {
          "id": 229599,
          "text": "Propanolol"
        },
        {
          "id": 229600,
          "text": "Warfarin"
        },
        {
          "id": 229601,
          "text": "Lovastatin"
        }
      ],
      "text": "Chronic use of which of the following medications is most likely to cause osteoporosis?",
      "unique_key": "Q5755091",
      "question_audio": null,
      "question_video": null,
      "map_id": 34052135,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Prednisone. Chronic use of glucocorticoids (such as prednisone) is a well-known cause of osteoporosis. Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis and occurs due to multiple mechanisms, including: Inhibition of osteoblast activity, leading to decreased bone formation. Increased osteoclast activity, resulting in excessive bone resorption. Reduced calcium absorption from the gut and increased renal calcium excretion, leading to secondary hyperparathyroidism, which further accelerates bone loss. Suppression of sex hormones (estrogen and testosterone), which are essential for bone maintenance. Because of these effects, chronic prednisone use increases the risk of fractures, especially in the spine and hips, making it the most likely drug to cause osteoporosis. Incorrect Options: B. Propranolol: Propranolol is a beta-blocker, primarily used to treat hypertension, arrhythmias, and migraines. Some studies suggest that beta-blockers may actually have a protective effect on bone by reducing bone resorption, although this is not fully established. It does not contribute to osteoporosis. C. Warfarin: Warfarin is an anticoagulant that inhibits vitamin K-dependent clotting factors. While vitamin K is involved in bone metabolism, long-term warfarin use has only a mild association with reduced bone density, but it is not a major cause of osteoporosis compared to glucocorticoids. D. Lovastatin: Lovastatin is a statin used to lower cholesterol levels. Some studies indicate that statins may have a mild protective effect on bone by stimulating osteoblast activity. There is no strong evidence linking lovastatin to osteoporosis.",
      "correct_choice_id": 229598,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/46353321700145109/46353321700145109.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/46353321700145109/46353321700145109.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54437,
      "choices": [
        {
          "id": 229602,
          "text": "Corticotropin"
        },
        {
          "id": 229603,
          "text": "hCG"
        },
        {
          "id": 229604,
          "text": "Desmopressin"
        },
        {
          "id": 229605,
          "text": "Menotropins"
        }
      ],
      "text": "A 7-year old boy, Manoj underwent successful chemotherapy and cranial radiation for the treatment of acute lymphocytic leukemia. One month after the completion of therapy, the patient presented with excessive thirst and urination plus hypernatremia. Laboratory testing revealed pituitary diabetes insipidus. To correct these problem, thin patient is likely to be treated with",
      "unique_key": "Q7216413",
      "question_audio": null,
      "question_video": null,
      "map_id": 34406880,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Desmopressin. Desmopressin (DDAVP) is a synthetic analog of vasopressin (antidiuretic hormone, ADH) and is the drug of choice for central (pituitary) diabetes insipidus (DI). In this case, the child's cranial radiation likely damaged the hypothalamus or pituitary gland, leading to insufficient ADH secretion. ADH is responsible for water retention by acting on the renal collecting ducts to increase water reabsorption. Desmopressin mimics ADH and corrects excessive urination (polyuria), excessive thirst (polydipsia), and hypernatremia by reducing free water loss in urine. It has high selectivity for V2 receptors in the kidneys, leading to increased water reabsorption with minimal vasoconstrictive effects. Incorrect Options: (A) Corticotropin – Incorrect Corticotropin (ACTH) stimulates adrenal cortisol production but has no role in water balance or ADH deficiency. It is used for conditions like adrenal insufficiency and infantile spasms, but it would not help in diabetes insipidus. (B) hCG (Human Chorionic Gonadotropin) – Incorrect hCG is used to stimulate testosterone production in male hypogonadism and cryptorchidism. It has no role in treating ADH deficiency or diabetes insipidus. (D) Menotropins – Incorrect Menotropins contain FSH and LH, which are used to stimulate ovulation in women and spermatogenesis in men. They do not affect ADH secretion or water balance.",
      "correct_choice_id": 229604,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/42250181700145564/42250181700145564.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/42250181700145564/42250181700145564.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54438,
      "choices": [
        {
          "id": 229606,
          "text": "Octreotide"
        },
        {
          "id": 229607,
          "text": "Leuprolide"
        },
        {
          "id": 229608,
          "text": "Desmopressin"
        },
        {
          "id": 229609,
          "text": "Somatropin"
        }
      ],
      "text": "A 47-year old male, Kishore exhibited signs and symptoms of acromegaly. Radiologic studies showed the presence of a large pituitary tumor. Surgical treatment of the tumor was on partially effective in controlling the disease. At this point, which of the following drugs is most Likely to be used a8 pharmacological therapy",
      "unique_key": "Q2564683",
      "question_audio": null,
      "question_video": null,
      "map_id": 34690059,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Octreotide. Acromegaly is caused by excessive secretion of growth hormone (GH), usually due to a pituitary adenoma. While surgery is the primary treatment, many patients require additional pharmacological therapy if surgery is incomplete or ineffective. Octreotide is a somatostatin analog that inhibits GH secretion by acting on somatostatin receptors in the pituitary gland. It reduces GH levels, thereby decreasing IGF-1 (insulin-like growth factor-1) levels, which mediate most of the symptoms of acromegaly. Octreotide is long-acting and is the most commonly used drug in acromegaly when surgery is inadequate. Incorrect Options: (B) Leuprolide – Incorrect Leuprolide is a GnRH analog used for prostate cancer, endometriosis, and precocious puberty. It has no direct role in reducing GH or IGF-1 levels and is not effective for acromegaly. (C) Desmopressin – Incorrect Desmopressin is a synthetic vasopressin analog used for diabetes insipidus and bleeding disorders like hemophilia A. It has no effect on GH secretion and is not useful in acromegaly. (D) Somatropin – Incorrect Somatropin is recombinant GH, used for GH deficiency, Turner syndrome, and growth failure. Since acromegaly is caused by excess GH, giving more GH would worsen the condition.",
      "correct_choice_id": 229606,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/55950771700145577/55950771700145577.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/55950771700145577/55950771700145577.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54439,
      "choices": [
        {
          "id": 229610,
          "text": "Leuprolide"
        },
        {
          "id": 229611,
          "text": "Desmopressin"
        },
        {
          "id": 229612,
          "text": "Human gonadotropin hormone"
        },
        {
          "id": 229613,
          "text": "Bromocriptine"
        }
      ],
      "text": "A young female, Rama with amenorrhea, infertility and galactorrhoea was treated with a drug that successfully restored ovulation and menstruation. Before being given the drug, the women was carefully questioned about previous mental health problems, which she did not have. She was advised to take the drug orally, the drug used to treat this patient was probably",
      "unique_key": "Q9922379",
      "question_audio": null,
      "question_video": null,
      "map_id": 34566821,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Bromocriptine. The patient has amenorrhea, infertility, and galactorrhea, which are classic symptoms of hyperprolactinemia. Hyperprolactinemia is commonly caused by a prolactin-secreting pituitary adenoma (prolactinoma) or other conditions that increase prolactin levels, leading to suppression of gonadotropin-releasing hormone (GnRH), infertility, and menstrual disturbances. Bromocriptine is a dopamine agonist that acts on D2 receptors in the pituitary gland to inhibit prolactin secretion. By reducing prolactin levels, bromocriptine restores normal ovulation and menstruation, improving fertility. Careful psychiatric history is taken before prescribing the drug because dopamine agonists can cause psychiatric side effects, such as hallucinations or mood disturbances. Bromocriptine is administered orally and is a well-established treatment for hyperprolactinemia-induced amenorrhea and infertility. Incorrect Options: (A) Leuprolide – Incorrect Leuprolide is a GnRH analog used for conditions like endometriosis, precocious puberty, and prostate cancer. It does not lower prolactin levels and is not useful in treating hyperprolactinemia. (B) Desmopressin – Incorrect Desmopressin is a vasopressin analog used to treat diabetes insipidus and bleeding disorders. It has no role in prolactin regulation or ovulation restoration. (C) Human Gonadotropin Hormone (hCG) – Incorrect hCG is used to stimulate ovulation in cases of anovulation due to LH deficiency. However, it does not lower prolactin levels and is not effective for hyperprolactinemia-induced amenorrhea.",
      "correct_choice_id": 229613,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/62201111700145591/62201111700145591.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/62201111700145591/62201111700145591.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54440,
      "choices": [
        {
          "id": 229614,
          "text": "Reserpine"
        },
        {
          "id": 229615,
          "text": "Haloperidol"
        },
        {
          "id": 229616,
          "text": "Bromocriptine"
        },
        {
          "id": 229617,
          "text": "Chlorpromazine"
        }
      ],
      "text": "Which of the following drugs Do Not cause hyper-prolactinemia?",
      "unique_key": "Q2574214",
      "question_audio": null,
      "question_video": null,
      "map_id": 34178513,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Bromocriptine. Bromocriptine is a dopamine (D2) receptor agonist, which means it stimulates dopamine receptors in the anterior pituitary gland. Dopamine naturally inhibits the secretion of prolactin by suppressing prolactin-producing lactotroph cells in the pituitary. Therefore, bromocriptine lowers prolactin levels and is actually used to treat hyperprolactinemia caused by conditions like prolactin-secreting pituitary adenomas (prolactinomas). Incorrect Options: (A) Reserpine – Incorrect Reserpine is an antihypertensive drug that works by depleting dopamine, norepinephrine, and serotonin from nerve terminals. Since dopamine inhibits prolactin release, depletion of dopamine leads to increased prolactin levels and can cause hyperprolactinemia. (B) Haloperidol – Incorrect Haloperidol is an antipsychotic (D2 receptor antagonist) used to treat schizophrenia and other psychotic disorders. It blocks dopamine receptors, thereby removing dopamine’s inhibitory effect on prolactin, leading to hyperprolactinemia, galactorrhea, and menstrual disturbances. (D) Chlorpromazine – Incorrect Chlorpromazine is a first-generation antipsychotic (D2 receptor antagonist) that, like haloperidol, blocks dopamine receptors in the pituitary. This increases prolactin secretion, leading to hyperprolactinemia, galactorrhea, and menstrual irregularities.",
      "correct_choice_id": 229616,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/55172451700145604/55172451700145604.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/55172451700145604/55172451700145604.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54441,
      "choices": [
        {
          "id": 229618,
          "text": "Can be given orally"
        },
        {
          "id": 229619,
          "text": "Initially stimulates release of LH and FSFI"
        },
        {
          "id": 229620,
          "text": "Must be given in a pulsatile fashion"
        },
        {
          "id": 229621,
          "text": "Immediately reduces gonadotropin secretion"
        }
      ],
      "text": "Important difference between leuprolide and ganirelix is that ganirelix",
      "unique_key": "Q1011043",
      "question_audio": null,
      "question_video": null,
      "map_id": 34983241,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) immediately reduces gonadotropin secretion. Ganirelix is a gonadotropin-releasing hormone (GnRH) antagonist, which means it directly blocks GnRH receptors in the anterior pituitary. As a result, it immediately inhibits the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This prevents the LH surge, making it useful in controlled ovarian stimulation during in vitro fertilization (IVF) to prevent premature ovulation. In contrast, Leuprolide is a GnRH agonist, which initially stimulates gonadotropin release before eventually downregulating GnRH receptors due to continuous stimulation. This leads to a delayed suppression of gonadotropin secretion. Incorrect Options: (A) Can be given orally – Incorrect Ganirelix is administered via subcutaneous injection, not orally, because peptide-based drugs like GnRH antagonists are broken down in the gastrointestinal tract and would not be effective if taken orally. (B) Initially stimulates release of LH and FSH – Incorrect This statement describes Leuprolide, a GnRH agonist, which initially increases gonadotropin levels before causing receptor desensitization and suppression. Ganirelix, as a GnRH antagonist, immediately inhibits gonadotropin release and does not cause an initial surge. (C) Must be given in a pulsatile fashion – Incorrect GnRH agonists, when given in a pulsatile manner, mimic natural GnRH secretion and stimulate gonadotropin release. Ganirelix is a GnRH antagonist and does not require pulsatile administration—it works through direct receptor blockade.",
      "correct_choice_id": 229621,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/61577021700145633/61577021700145633.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/61577021700145633/61577021700145633.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54442,
      "choices": [
        {
          "id": 229622,
          "text": "Bromocriptine"
        },
        {
          "id": 229623,
          "text": "Nafarelin"
        },
        {
          "id": 229624,
          "text": "Octreotide"
        },
        {
          "id": 229625,
          "text": "Somatostatin"
        }
      ],
      "text": "All of the following agents are useful in acromegaly EXCEPT",
      "unique_key": "Q5125061",
      "question_audio": null,
      "question_video": null,
      "map_id": 34278735,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Nafarelin. Nafarelin is a gonadotropin-releasing hormone (GnRH) agonist, which is primarily used for conditions like endometriosis, central precocious puberty, and prostate cancer. It does not have a role in acromegaly, a condition caused by excessive growth hormone (GH) secretion from a pituitary adenoma. Since Nafarelin does not suppress GH release or antagonize its effects, it is not useful in the treatment of acromegaly. Incorrect Options: (A) Bromocriptine – Useful Bromocriptine is a dopamine agonist that can inhibit GH secretion in some patients with acromegaly, especially those whose tumors also secrete prolactin. It reduces GH levels and clinical symptoms in some cases, though it is less effective than somatostatin analogs. (C) Octreotide – Useful Octreotide is a somatostatin analog that potently inhibits GH secretion by binding to somatostatin receptors in the pituitary. It is one of the first-line medical therapies for acromegaly, effectively reducing GH levels and tumor size in many patients. (D) Somatostatin – Useful Somatostatin is a natural inhibitor of GH secretion and is the hormone from which drugs like Octreotide and Lanreotide are derived. Although it has a very short half-life, it plays a role in GH regulation, and its synthetic analogs are clinically useful in acromegaly.",
      "correct_choice_id": 229623,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/70455511700145816/70455511700145816.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/70455511700145816/70455511700145816.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54443,
      "choices": [
        {
          "id": 229626,
          "text": "Raloxifene"
        },
        {
          "id": 229627,
          "text": "Teriparatide"
        },
        {
          "id": 229628,
          "text": "Denosumab"
        },
        {
          "id": 229629,
          "text": "Alendronate"
        }
      ],
      "text": "A drug used in osteoporosis which doesn’t act by decreasing bone resorption is",
      "unique_key": "Q8360604",
      "question_audio": null,
      "question_video": null,
      "map_id": 34859925,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Teriparatide. Unlike most osteoporosis treatments that work by decreasing bone resorption, teriparatide is an anabolic (bone-forming) agent. It is a recombinant form of parathyroid hormone (PTH 1-34) that stimulates osteoblast activity, leading to increased bone formation. Teriparatide is used in severe osteoporosis, particularly in patients at high risk of fractures, and is the only osteoporosis drug that primarily increases bone formation rather than reducing bone resorption. Its mechanism contrasts with anti-resorptive agents like bisphosphonates, denosumab, and raloxifene. Explanation of Incorrect Options: (A) Raloxifene: This is incorrect because raloxifene is a Selective Estrogen Receptor Modulator (SERM) that reduces bone resorption. It mimics estrogen’s effects on bones by inhibiting osteoclast activity, thereby preserving bone density. (C) Denosumab: Incorrect, as denosumab is a monoclonal antibody that targets RANK ligand (RANKL), a key factor in osteoclast activation. By inhibiting RANKL, denosumab prevents osteoclast formation and reduces bone resorption. (D) Alendronate: Incorrect because alendronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption. It binds to bone minerals and disrupts osteoclast function, thereby slowing down bone loss.",
      "correct_choice_id": 229627,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37481081700146182/37481081700146182.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37481081700146182/37481081700146182.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54444,
      "choices": [
        {
          "id": 229630,
          "text": "Osteomalacia"
        },
        {
          "id": 229631,
          "text": "Osteoporosis"
        },
        {
          "id": 229632,
          "text": "Hypercalcemia"
        },
        {
          "id": 229633,
          "text": "Paget’s disease"
        }
      ],
      "text": "Subcutaneous Calcitonin is used in",
      "unique_key": "Q9519407",
      "question_audio": null,
      "question_video": null,
      "map_id": 34623177,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Paget’s disease. Calcitonin is a hormone that inhibits osteoclast activity, thereby reducing bone resorption and bone turnover. It is particularly effective in Paget’s disease of bone, a condition characterized by excessive and disorganized bone remodeling, leading to bone pain, deformities, and fractures. Subcutaneous or intranasal calcitonin helps alleviate bone pain and slow disease progression by reducing osteoclastic activity. While it is less commonly used today due to the availability of bisphosphonates, calcitonin remains an alternative option in patients who cannot tolerate bisphosphonates or need short-term pain relief. Explanation of Incorrect Options: (A) Osteomalacia: Incorrect because osteomalacia results from vitamin D deficiency, leading to defective bone mineralization. Calcitonin does not correct the underlying defect; instead, vitamin D and calcium supplementation are the main treatments. (B) Osteoporosis: Incorrect, as calcitonin has limited efficacy in osteoporosis compared to bisphosphonates, denosumab, or teriparatide. While it reduces bone resorption, its effect on increasing bone density is weak, making it a less preferred treatment. It may be used in some cases for pain relief from osteoporotic fractures but is not a first-line therapy. (C) Hypercalcemia: Partially correct but not the best choice. Calcitonin can lower serum calcium levels by inhibiting bone resorption, making it useful in acute hypercalcemia, particularly in conditions like malignancy-associated hypercalcemia. However, it is less potent than bisphosphonates or denosumab and is used only in short-term management due to tachyphylaxis (loss of effect over time).",
      "correct_choice_id": 229633,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/44896851700146194/44896851700146194.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/44896851700146194/44896851700146194.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54445,
      "choices": [
        {
          "id": 229634,
          "text": "Increases bone formation"
        },
        {
          "id": 229635,
          "text": "Decreases bone resorption"
        },
        {
          "id": 229636,
          "text": "Both A & B"
        },
        {
          "id": 229637,
          "text": "NONE"
        }
      ],
      "text": "Strontium ranelate",
      "unique_key": "Q7826025",
      "question_audio": null,
      "question_video": null,
      "map_id": 34144266,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Both A & B. Strontium ranelate is a unique osteoporosis drug that has a dual mechanism of action: it increases bone formation by stimulating osteoblast activity while simultaneously decreasing bone resorption by inhibiting osteoclast differentiation and function. This dual effect leads to increased bone mineral density (BMD) and a reduced risk of fractures, particularly in postmenopausal osteoporosis. Unlike bisphosphonates, which only reduce bone resorption, strontium ranelate promotes bone formation while maintaining structural integrity. However, its use has declined due to concerns about cardiovascular risks, including increased risk of heart attacks. Explanation of Incorrect Options: (A) Increases bone formation: While this is partially correct, it does not fully explain the drug's action. Strontium ranelate does promote bone formation, but it also reduces bone resorption, making option C more accurate. (B) Decreases bone resorption: Again, this is partially correct, as strontium ranelate inhibits osteoclast activity, reducing bone breakdown. However, since it also increases bone formation, this option does not fully capture its dual mechanism. (D) NONE: This is incorrect, as strontium ranelate has clear effects on both bone formation and resorption, making it an effective osteoporosis treatment despite its safety concerns.",
      "correct_choice_id": 229636,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/54565231700146205/54565231700146205.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/54565231700146205/54565231700146205.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54446,
      "choices": [
        {
          "id": 229638,
          "text": "Tamoxifen"
        },
        {
          "id": 229639,
          "text": "Zolendronate"
        },
        {
          "id": 229640,
          "text": "Calcitriol"
        },
        {
          "id": 229641,
          "text": "Strontium ranelate"
        }
      ],
      "text": "A drug which is known to cause osteonecrosis on IV administration is",
      "unique_key": "Q9591853",
      "question_audio": null,
      "question_video": null,
      "map_id": 34421840,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Zoledronate. Zoledronate (Zoledronic acid) is a potent bisphosphonate used in osteoporosis, Paget’s disease, and hypercalcemia of malignancy. It works by inhibiting osteoclast activity, thereby reducing bone resorption. However, a known adverse effect of intravenous (IV) bisphosphonates, particularly zoledronate, is osteonecrosis of the jaw (ONJ). ONJ is a serious condition characterized by bone necrosis, delayed healing, and exposure of bone in the oral cavity, often triggered by dental extractions or invasive dental procedures. The risk is higher in patients receiving high-dose IV bisphosphonates for cancer-related bone disease than in those taking it for osteoporosis. Explanation of Incorrect Options: (A) Tamoxifen: Incorrect, as tamoxifen is a Selective Estrogen Receptor Modulator (SERM) that helps preserve bone density in postmenopausal women. It does not cause osteonecrosis. Instead, it has been associated with a reduced risk of fractures in some studies. (C) Calcitriol: Incorrect, as calcitriol is the active form of vitamin D used to manage osteomalacia, hypocalcemia, and renal osteodystrophy. It plays a role in calcium absorption and bone mineralization but has no link to osteonecrosis. (D) Strontium ranelate: Incorrect, as strontium ranelate is a drug with both bone-forming and anti-resorptive properties. While it has been associated with cardiovascular risks, it is not linked to osteonecrosis of the jaw.",
      "correct_choice_id": 229639,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/74725011700146216/74725011700146216.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/74725011700146216/74725011700146216.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54447,
      "choices": [
        {
          "id": 229642,
          "text": "Etidronate"
        },
        {
          "id": 229643,
          "text": "Pamidronate"
        },
        {
          "id": 229644,
          "text": "Alendronate"
        },
        {
          "id": 229645,
          "text": "Risedronate"
        }
      ],
      "text": "Most potent Bisphosphonate among the following is",
      "unique_key": "Q4353263",
      "question_audio": null,
      "question_video": null,
      "map_id": 34524949,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Risedronate. Among the given options, risedronate is the most potent bisphosphonate due to its strong affinity for hydroxyapatite in bone and high inhibitory effect on osteoclast-mediated bone resorption. Bisphosphonates function by binding to bone mineral and inhibiting osteoclast activity, thereby reducing bone breakdown. Risedronate has a nitrogen-containing structure, which makes it significantly more potent than non-nitrogen bisphosphonates (like etidronate). It is used for osteoporosis, Paget’s disease, and other conditions associated with high bone turnover. Explanation of Incorrect Options: (A) Etidronate: Incorrect because etidronate is a first-generation (non-nitrogen-containing) bisphosphonate and is much less potent than newer nitrogen-containing bisphosphonates. It has weaker osteoclast inhibition and is rarely used today due to its lower efficacy and risk of impairing bone mineralization. (B) Pamidronate: Incorrect as pamidronate is more potent than etidronate but less potent than risedronate. It is primarily used intravenously for hypercalcemia of malignancy and Paget’s disease but is not the most potent bisphosphonate among the given choices. (C) Alendronate: Incorrect as alendronate is more potent than etidronate and pamidronate but still less potent than risedronate. It is commonly used for osteoporosis and Paget’s disease and is a highly effective anti-resorptive agent.",
      "correct_choice_id": 229645,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/45678971700146241/45678971700146241.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/45678971700146241/45678971700146241.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54448,
      "choices": [
        {
          "id": 229646,
          "text": "Use shorter acting steroids"
        },
        {
          "id": 229647,
          "text": "Use steroids for the shortest period of time"
        },
        {
          "id": 229648,
          "text": "Switch to alternate-day therapy if possible"
        },
        {
          "id": 229649,
          "text": "Give the dose divided into three times daily so that peak steroid concentration is reduced"
        }
      ],
      "text": "Following are measures that minimize HPA axis suppression except",
      "unique_key": "Q2328312",
      "question_audio": null,
      "question_video": null,
      "map_id": 34866825,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Give the dose divided into three times daily so that peak steroid concentration is reduced. Dividing the dose into multiple daily administrations (e.g., three times daily) actually increases HPA axis suppression, as it leads to continuous exposure to corticosteroids without allowing sufficient recovery time for endogenous cortisol production. The hypothalamic-pituitary-adrenal (HPA) axis is suppressed when exogenous steroids provide sustained high levels of glucocorticoids, which reduce the body's natural production of cortisol. To minimize suppression, strategies focus on mimicking physiological cortisol secretion patterns, such as single morning dosing or alternate-day therapy. Explanation of Incorrect Options: (A) Use shorter-acting steroids: Incorrect, as using shorter-acting steroids (e.g., hydrocortisone instead of dexamethasone or prednisolone) helps minimize HPA suppression. Short-acting steroids have a quicker clearance, reducing prolonged adrenal suppression compared to long-acting steroids. (B) Use steroids for the shortest period of time: Incorrect, as minimizing duration of steroid therapy is a key strategy to reduce HPA axis suppression. Prolonged use of steroids leads to negative feedback inhibition, preventing the adrenal glands from producing cortisol naturally. (C) Switch to alternate-day therapy if possible: Incorrect, as alternate-day therapy is one of the best ways to prevent HPA axis suppression. By allowing a day of steroid-free interval, the adrenal glands have time to recover and continue endogenous cortisol production. This is especially beneficial for patients on long-term glucocorticoid therapy.",
      "correct_choice_id": 229649,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/60827371700146270/60827371700146270.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/60827371700146270/60827371700146270.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54449,
      "choices": [
        {
          "id": 229650,
          "text": "Inhibit production of surfactant"
        },
        {
          "id": 229651,
          "text": "Increase the concentration of neutrophils in circulation"
        },
        {
          "id": 229652,
          "text": "Inhibit function of macrophages"
        },
        {
          "id": 229653,
          "text": "Reduce synthesis of prostaglandins"
        }
      ],
      "text": "All of the following statements regarding corticosteroids are correct except",
      "unique_key": "Q4797740",
      "question_audio": null,
      "question_video": null,
      "map_id": 34994724,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Inhibit production of surfactant. This statement is incorrect because corticosteroids actually promote surfactant production, rather than inhibiting it. Surfactant is a lipid-protein substance produced by alveolar type II cells in the lungs, which reduces surface tension and prevents alveolar collapse. Glucocorticoids, especially betamethasone and dexamethasone, are used in pregnant women at risk of preterm birth to accelerate fetal lung maturity and increase surfactant production. This helps reduce the incidence of neonatal respiratory distress syndrome (RDS) in preterm infants. Explanation of Incorrect Options: (B) Increase the concentration of neutrophils in circulation: Correct statement. Corticosteroids increase circulating neutrophil counts by reducing neutrophil migration from blood to tissues and inhibiting neutrophil apoptosis. However, despite the increase in blood neutrophils, their overall immune function is suppressed, which can contribute to increased infection risk. (C) Inhibit function of macrophages: Correct statement. Corticosteroids suppress the phagocytic and antigen-presenting functions of macrophages, leading to reduced inflammation and immune response. This contributes to their immunosuppressive effects, making them useful in autoimmune diseases, allergies, and transplant rejection prevention. (D) Reduce synthesis of prostaglandins: Correct statement. Corticosteroids inhibit phospholipase A2 via increased production of lipocortin (annexin-1), thereby reducing arachidonic acid release, which is a precursor for prostaglandins and leukotrienes. This is a key mechanism behind their anti-inflammatory effects, as prostaglandins play a major role in inflammation, pain, and fever.",
      "correct_choice_id": 229650,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25341511700146284/25341511700146284.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25341511700146284/25341511700146284.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54450,
      "choices": [
        {
          "id": 229654,
          "text": "Cetrorelix"
        },
        {
          "id": 229655,
          "text": "Degarelix"
        },
        {
          "id": 229656,
          "text": "Elagolix"
        },
        {
          "id": 229657,
          "text": "Abarelix"
        }
      ],
      "text": "Which of the following GnRH antagonists used for the management of moderate to severe pain associated with endometriosis",
      "unique_key": "Q4077680",
      "question_audio": null,
      "question_video": null,
      "map_id": 34632650,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Elagolix. Elagolix is an orally active GnRH antagonist specifically approved for the management of moderate to severe pain associated with endometriosis. It works by competitively inhibiting GnRH receptors in the pituitary gland, leading to a dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This suppression reduces ovarian estrogen production, which is essential for the growth and maintenance of endometrial tissue. Unlike GnRH agonists, which initially cause a temporary hormone surge before downregulation, elagolix rapidly reduces estrogen levels without an initial flare, making it a preferred option for treating endometriosis-related pain. Explanation of Incorrect Options: (A) Cetrorelix: Incorrect because cetrorelix is a GnRH antagonist primarily used in assisted reproductive technology (ART) to prevent premature ovulation in controlled ovarian stimulation cycles. It does not have an indication for endometriosis-related pain management. (B) Degarelix: Incorrect because degarelix is a GnRH antagonist used in the treatment of advanced prostate cancer. It rapidly suppresses testosterone production, but it is not used for endometriosis or gynecological conditions. (D) Abarelix: Incorrect because abarelix is another GnRH antagonist used for prostate cancer treatment. It reduces testosterone levels in males but is not indicated for endometriosis management.",
      "correct_choice_id": 229656,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/66730781700146342/66730781700146342.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/66730781700146342/66730781700146342.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54451,
      "choices": [
        {
          "id": 229658,
          "text": "the partial agonistic action of Methylergometrine on 5-HT2 receptors"
        },
        {
          "id": 229659,
          "text": "The agonistic action of Methylergometrine on dopamine receptors"
        },
        {
          "id": 229660,
          "text": "The partial agonistic action of Methylergometrine on a-adrenergic receptors"
        },
        {
          "id": 229661,
          "text": "None of the above"
        }
      ],
      "text": "A female was given a higher dose of Methylergometrine for post-partum hemorrhage and continued after that for several days. Mother had very little milk secretion for 1 month. The reason for this is",
      "unique_key": "Q1612263",
      "question_audio": null,
      "question_video": null,
      "map_id": 34206291,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) The agonistic action of Methylergometrine on dopamine receptors. Methylergometrine, a semi-synthetic ergot alkaloid, acts as an agonist at dopamine (D2) receptors, leading to inhibition of prolactin secretion. Prolactin is essential for lactation, and its suppression results in reduced milk production. Since methylergometrine was given at a high dose and continued for several days, prolactin levels remained suppressed, leading to poor milk secretion for an extended period. Explanation of Incorrect Options: (A) The partial agonistic action of Methylergometrine on 5-HT2 receptors – Incorrect. While methylergometrine does have partial agonist activity at serotonin (5-HT2) receptors, this effect is primarily responsible for its vasoconstrictive properties, which help in uterine contraction to control postpartum hemorrhage. However, 5-HT2 receptor activity does not significantly influence prolactin secretion, so this is not the reason for reduced lactation. (C) The partial agonistic action of Methylergometrine on α-adrenergic receptors – Incorrect. Methylergometrine has partial agonist and antagonist effects on α-adrenergic receptors, which contribute to vasoconstriction and increased blood pressure. However, α-adrenergic receptor activity is not directly related to prolactin secretion or lactation suppression, making this option incorrect. (D) None of the above – Incorrect. As discussed, methylergometrine’s agonistic action on dopamine (D2) receptors inhibits prolactin release, which directly explains the reduced milk production, making option (B) the correct choice.",
      "correct_choice_id": 229659,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/70445611700146642/70445611700146642.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/70445611700146642/70445611700146642.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54452,
      "choices": [
        {
          "id": 229662,
          "text": "Buserelin"
        },
        {
          "id": 229663,
          "text": "Leuprolide"
        },
        {
          "id": 229664,
          "text": "Tesamorelin"
        },
        {
          "id": 229665,
          "text": "Goserelin"
        }
      ],
      "text": "All the given drugs are GnRH agonists except",
      "unique_key": "Q9432458",
      "question_audio": null,
      "question_video": null,
      "map_id": 34631143,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Tesamorelin. Tesamorelin is not a GnRH agonist; instead, it is a synthetic analog of growth hormone-releasing hormone (GHRH). It stimulates the release of growth hormone from the pituitary gland and is primarily used in the treatment of HIV-associated lipodystrophy to reduce visceral fat. Since Tesamorelin does not act on the gonadotropin-releasing hormone (GnRH) receptors, it does not belong to the GnRH agonist class. Explanation of Incorrect Options: (A) Buserelin – Incorrect. Buserelin is a GnRH agonist used in the treatment of hormone-dependent conditions like prostate cancer, endometriosis, and precocious puberty. It works by initially stimulating the release of gonadotropins (LH and FSH) before causing receptor desensitization, leading to reduced sex hormone levels. (B) Leuprolide – Incorrect. Leuprolide is a GnRH agonist commonly used in the treatment of prostate cancer, endometriosis, uterine fibroids, and precocious puberty. It initially increases LH and FSH secretion but eventually suppresses them, leading to a decrease in estrogen and testosterone levels. (D) Goserelin – Incorrect. Goserelin is another GnRH agonist used in the management of prostate cancer, breast cancer, and endometriosis. Like other GnRH agonists, it initially stimulates gonadotropin secretion before downregulating GnRH receptors, resulting in hormonal suppression.",
      "correct_choice_id": 229664,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/51281941700146654/51281941700146654.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/51281941700146654/51281941700146654.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54453,
      "choices": [
        {
          "id": 229666,
          "text": "Cabergoline"
        },
        {
          "id": 229667,
          "text": "Pergolide"
        },
        {
          "id": 229668,
          "text": "Both a and b"
        },
        {
          "id": 229669,
          "text": "None of the above"
        }
      ],
      "text": "The following drug is/are associated with valvar heart disease",
      "unique_key": "Q8705679",
      "question_audio": null,
      "question_video": null,
      "map_id": 34874877,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Both A and B. Cabergoline and Pergolide are ergot-derived dopamine agonists that have been associated with an increased risk of valvular heart disease. This is primarily attributed to their agonistic activity on serotonin 5-HT?B receptors, which are expressed on cardiac valvular interstitial cells. Prolonged stimulation of these receptors leads to fibrotic changes in heart valves, resulting in valvulopathy. Due to these concerns, Pergolide was withdrawn from the U.S. market, while Cabergoline use is now restricted, particularly at higher doses. Explanation of Incorrect Options: (A) Cabergoline – Incorrect in isolation. While Cabergoline has been linked to valvular fibrosis due to its 5-HT?B receptor activation, the question asks for all drugs associated with valvular heart disease, making option C the more complete choice. (B) Pergolide – Incorrect in isolation. Similar to Cabergoline, Pergolide was implicated in cardiac valvulopathy and withdrawn from the market in several countries due to safety concerns. However, since both drugs share this risk, option C remains the most accurate response. (D) None of the above – Incorrect. Given the well-documented association between Cabergoline, Pergolide, and valvular heart disease, this option is not a valid choice.",
      "correct_choice_id": 229668,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75603761700146667/75603761700146667.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75603761700146667/75603761700146667.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54454,
      "choices": [
        {
          "id": 229670,
          "text": "Acute Stomatitis"
        },
        {
          "id": 229671,
          "text": "Carcinoid Syndrome"
        },
        {
          "id": 229672,
          "text": "Acromegaly"
        },
        {
          "id": 229673,
          "text": "Acute Pancreatitis"
        }
      ],
      "text": "Which of the following is not a therapeutic indication of Octreotide",
      "unique_key": "Q2938943",
      "question_audio": null,
      "question_video": null,
      "map_id": 34587188,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Acute Stomatitis. Octreotide is not indicated for the treatment of acute stomatitis, which is an inflammatory condition affecting the mouth and lips, often caused by infections, chemotherapy, or autoimmune disorders. Octreotide, a somatostatin analog, is primarily used for conditions involving excessive hormone secretion, but it does not play a role in managing stomatitis. Explanation of Incorrect Options: (B) Carcinoid Syndrome – Incorrect. Octreotide is widely used in the treatment of carcinoid syndrome, which occurs due to excess serotonin secretion from neuroendocrine tumors. Octreotide helps control symptoms such as flushing, diarrhea, and wheezing by inhibiting the release of vasoactive substances from the tumor. (C) Acromegaly – Incorrect. Acromegaly is caused by excessive growth hormone (GH) secretion, usually due to a pituitary adenoma. Octreotide, by mimicking somatostatin, inhibits GH release and is a key treatment option in acromegaly, particularly when surgery is not feasible or as an adjunct to other therapies. (D) Acute Pancreatitis – Incorrect. Octreotide is sometimes used in acute pancreatitis to reduce pancreatic secretions and inflammation, although its clinical benefit remains debated. It is particularly considered in cases of severe pancreatitis with complications.",
      "correct_choice_id": 229670,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37452951700146679/37452951700146679.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37452951700146679/37452951700146679.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54455,
      "choices": [
        {
          "id": 229674,
          "text": "Prolactinoma"
        },
        {
          "id": 229675,
          "text": "Pituitary dwarfism"
        },
        {
          "id": 229676,
          "text": "Gigantism"
        },
        {
          "id": 229677,
          "text": "HIV-associated lipodystrophy"
        }
      ],
      "text": "Tesamorelin is used in",
      "unique_key": "Q2545172",
      "question_audio": null,
      "question_video": null,
      "map_id": 34942641,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) HIV-associated lipodystrophy. Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the secretion of growth hormone (GH) from the pituitary gland. It is primarily used to reduce excess visceral fat accumulation in patients with HIV-associated lipodystrophy. This condition, often seen in individuals on long-term antiretroviral therapy, leads to abnormal fat distribution, increasing metabolic complications. Tesamorelin helps by reducing visceral fat while maintaining peripheral fat stores, thus improving metabolic profiles in affected patients. Explanation of Incorrect Options: (A) Prolactinoma – Incorrect. Prolactinoma is a pituitary tumor that leads to excessive secretion of prolactin, causing symptoms such as galactorrhea, infertility, and hypogonadism. The treatment of choice is dopamine agonists like Cabergoline or Bromocriptine, not Tesamorelin, as it does not affect prolactin levels. (B) Pituitary Dwarfism – Incorrect. Pituitary dwarfism (growth hormone deficiency) results from insufficient GH secretion, leading to stunted growth. While Tesamorelin can stimulate GH release, it is not the first-line treatment for GH deficiency. Instead, recombinant human growth hormone (somatropin) is preferred. (C) Gigantism – Incorrect. Gigantism is caused by excess GH secretion before the closure of growth plates, usually due to a pituitary adenoma. The goal of treatment is to reduce GH levels, typically through somatostatin analogs (Octreotide), dopamine agonists, or surgery. Since Tesamorelin stimulates GH release, it would worsen gigantism rather than treat it.",
      "correct_choice_id": 229677,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/69981531700146758/69981531700146758.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/69981531700146758/69981531700146758.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54456,
      "choices": [
        {
          "id": 229678,
          "text": "The most common adverse effect is nausea"
        },
        {
          "id": 229679,
          "text": "Administered as a subcutaneous injection prior to meals"
        },
        {
          "id": 229680,
          "text": "Approved for treatment of types 1 and 2 diabetes"
        },
        {
          "id": 229681,
          "text": "Pramlintide can be given in patients with gastroparesis"
        }
      ],
      "text": "Which of the following is incorrect ABOUT PRAMLINTIDE",
      "unique_key": "Q5568662",
      "question_audio": null,
      "question_video": null,
      "map_id": 34502060,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Pramlintide can be given in patients with gastroparesis, which is incorrect. Pramlintide is contraindicated in patients with gastroparesis because it slows gastric emptying, which can worsen symptoms like nausea, bloating, and delayed digestion in these patients. Gastroparesis is already characterized by impaired gastric motility, and pramlintide's mechanism of action would further exacerbate this condition, leading to potential complications such as erratic blood glucose control. Explanation of Incorrect Options: (A) The most common adverse effect is nausea – Correct. Nausea is the most frequent side effect of pramlintide, especially when initiating therapy. This occurs due to its gastric emptying delay and central appetite-suppressing effects. However, this side effect often diminishes over time as the body adjusts to the medication. (B) Administered as a subcutaneous injection prior to meals – Correct. Pramlintide is administered subcutaneously before meals to help control postprandial glucose levels. It mimics amylin, a hormone that regulates glucose by slowing gastric emptying, reducing glucagon secretion, and increasing satiety. (C) Approved for treatment of types 1 and 2 diabetes – Correct. Pramlintide is one of the few non-insulin therapies approved for both Type 1 and Type 2 diabetes. Since amylin is deficient in both types of diabetes, pramlintide supplementation helps improve postprandial glycemic control in both patient groups.",
      "correct_choice_id": 229681,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/45917141700146869/45917141700146869.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/45917141700146869/45917141700146869.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54457,
      "choices": [
        {
          "id": 229682,
          "text": "Methotrexate"
        },
        {
          "id": 229683,
          "text": "Salbutamol"
        },
        {
          "id": 229684,
          "text": "Indomethacin"
        },
        {
          "id": 229685,
          "text": "Prednisolone"
        }
      ],
      "text": "A 62-year-old female, Phoolwati presents to the emergency with acute severe low back pain after too quickly sitting down onto a chair. She has a history of rheumatoid arthritis and bronchial asthma. She reports that the was on many medications for several years. X-ray shows a fracture of the fifth lumbar vertebra. Which of the following drugs are likely responsible for the patient's complaints?",
      "unique_key": "Q7825223",
      "question_audio": null,
      "question_video": null,
      "map_id": 34069741,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Prednisolone. Long-term use of glucocorticoids like prednisolone is a well-known cause of osteoporosis, which significantly increases the risk of vertebral fractures even with minimal trauma. Glucocorticoids reduce bone formation by inhibiting osteoblast activity, increasing bone resorption, and decreasing calcium absorption in the intestines. This leads to glucocorticoid-induced osteoporosis (GIOP), making bones weak and prone to fractures, particularly in weight-bearing structures like the lumbar vertebrae. Given that the patient has rheumatoid arthritis and asthma, both of which are often treated with long-term corticosteroids, prednisolone is the most likely culprit for her vertebral fracture. Explanation of Incorrect Options: (A) Methotrexate – Incorrect. Methotrexate is used to manage rheumatoid arthritis, but it is not a primary cause of osteoporosis or fractures. Although high doses over long periods may have some bone toxicity, the degree of bone loss is far less compared to corticosteroids. The patient's acute vertebral fracture is more consistent with corticosteroid-induced osteoporosis rather than methotrexate use. (B) Salbutamol – Incorrect. Salbutamol is a ?2-adrenergic agonist used in bronchial asthma. It primarily affects smooth muscle relaxation in the bronchi and has no direct effect on bone density. While chronic ?-agonist use may cause hypokalemia and muscle weakness, it does not contribute to osteoporosis or fractures. (C) Indomethacin – Incorrect. Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) used for pain and inflammation in conditions like rheumatoid arthritis. NSAIDs do not significantly affect bone metabolism or lead to osteoporosis. However, long-term NSAID use can increase the risk of gastrointestinal bleeding and renal dysfunction, but it is not a direct cause of fractures.",
      "correct_choice_id": 229685,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28645161700146881/28645161700146881.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28645161700146881/28645161700146881.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54458,
      "choices": [
        {
          "id": 229686,
          "text": "Polycystic ovarian disease"
        },
        {
          "id": 229687,
          "text": "Hormone responsive breast carcinoma"
        },
        {
          "id": 229688,
          "text": "Osteoporosis"
        },
        {
          "id": 229689,
          "text": "Hyperparathyroidism"
        }
      ],
      "text": "Teriparatide can be used for the treatment of",
      "unique_key": "Q4030459",
      "question_audio": null,
      "question_video": null,
      "map_id": 34412286,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Osteoporosis. Teriparatide is a recombinant form of parathyroid hormone (PTH 1-34) used in the treatment of osteoporosis, particularly in postmenopausal women and men at high risk for fractures. Unlike anti-resorptive drugs (such as bisphosphonates), teriparatide stimulates new bone formation by increasing the activity of osteoblasts, thereby enhancing bone mass and strength. It is particularly beneficial in severe osteoporosis with a high risk of fractures, including vertebral and non-vertebral fractures. Due to its mechanism, teriparatide is the only approved anabolic (bone-building) therapy for osteoporosis. Explanation of Incorrect Options: (A) Polycystic Ovarian Disease (PCOD) – Incorrect. Teriparatide has no role in the management of PCOD/PCOS, which is primarily managed with hormonal therapy (oral contraceptives), insulin sensitizers (metformin), and lifestyle modifications. PCOD is a reproductive and metabolic disorder rather than a bone-related condition, making teriparatide an unsuitable treatment. (B) Hormone-Responsive Breast Carcinoma – Incorrect. Hormone-responsive breast cancer is typically treated with selective estrogen receptor modulators (SERMs) like tamoxifen, aromatase inhibitors (letrozole, anastrozole), and sometimes chemotherapy. Teriparatide does not influence estrogen or hormonal pathways involved in breast cancer progression, so it has no therapeutic use in this condition. (D) Hyperparathyroidism – Incorrect. Hyperparathyroidism is caused by excessive secretion of parathyroid hormone (PTH), which leads to bone resorption, hypercalcemia, and potential kidney stones. Since teriparatide is a PTH analog, using it in hyperparathyroidism would worsen the condition rather than treating it. The treatment for hyperparathyroidism usually involves surgery (parathyroidectomy) or medications like calcimimetics (cinacalcet) to reduce PTH levels.",
      "correct_choice_id": 229688,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/4553361700146929/4553361700146929.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/4553361700146929/4553361700146929.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54459,
      "choices": [
        {
          "id": 229690,
          "text": "Osteoporosis"
        },
        {
          "id": 229691,
          "text": "Hyperparathyroidism"
        },
        {
          "id": 229692,
          "text": "Diabetes mellitus"
        },
        {
          "id": 229693,
          "text": "Anovulatory infertility"
        }
      ],
      "text": "Exenatide is a newer drug proposed to be used in the treatment of",
      "unique_key": "Q7087653",
      "question_audio": null,
      "question_video": null,
      "map_id": 34895935,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Diabetes mellitus. Exenatide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that is used in the treatment of type 2 diabetes mellitus. It enhances insulin secretion in a glucose-dependent manner, suppresses glucagon secretion, slows gastric emptying, and promotes satiety, leading to better glycemic control. It helps lower postprandial glucose levels and is also associated with weight loss, making it particularly useful in overweight diabetic patients. Due to its mechanism of action, exenatide does not cause hypoglycemia when used alone, unlike insulin or sulfonylureas. Explanation of Incorrect Options: (A) Osteoporosis – Incorrect. Osteoporosis is a bone metabolic disorder characterized by reduced bone mass and increased fracture risk. The treatment of osteoporosis typically includes bisphosphonates (alendronate, zoledronate), selective estrogen receptor modulators (raloxifene), and anabolic agents (teriparatide, romosozumab). Exenatide does not play any role in bone metabolism or bone-strengthening processes. (B) Hyperparathyroidism – Incorrect. Hyperparathyroidism results from excessive secretion of parathyroid hormone (PTH), leading to hypercalcemia, bone resorption, and kidney stones. The primary treatment for this condition includes surgical removal of the overactive parathyroid gland or calcimimetic drugs like cinacalcet, which reduce PTH secretion. Exenatide has no role in regulating PTH levels or calcium metabolism. (D) Anovulatory Infertility – Incorrect. Anovulatory infertility is commonly associated with polycystic ovarian syndrome (PCOS) or hormonal imbalances. Treatment typically involves ovulation-inducing agents like clomiphene citrate, letrozole, gonadotropins, or metformin (for insulin resistance-related cases). Since exenatide is used for diabetes management, it does not directly impact ovulation or fertility treatments.",
      "correct_choice_id": 229692,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/49896291700147016/49896291700147016.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/49896291700147016/49896291700147016.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54460,
      "choices": [
        {
          "id": 229694,
          "text": "Salbutamol"
        },
        {
          "id": 229695,
          "text": "Isoprenaline"
        },
        {
          "id": 229696,
          "text": "Ritodrine"
        },
        {
          "id": 229697,
          "text": "Terbutaline"
        }
      ],
      "text": "Which of the following is an adrenergic drug preferred for arresting labour?",
      "unique_key": "Q1430434",
      "question_audio": null,
      "question_video": null,
      "map_id": 34002672,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Ritodrine. Ritodrine is a β2-adrenergic agonist that is specifically used as a tocolytic agent (a drug that inhibits uterine contractions) to arrest preterm labor. It works by stimulating β2 receptors in the myometrium, leading to relaxation of uterine smooth muscles. This reduces uterine contractions and delays labor, providing time for fetal lung maturation (often aided by corticosteroids like betamethasone). Ritodrine is one of the first-line drugs used for the management of preterm labor. Explanation of Incorrect Options: (A) Salbutamol – Incorrect. Salbutamol (albuterol) is primarily used as a bronchodilator in the treatment of asthma and chronic obstructive pulmonary disease (COPD). While it has some β2-agonist effects that could relax uterine muscles, it is not the preferred drug for tocolysis. Ritodrine and terbutaline are more commonly used for this purpose. (B) Isoprenaline – Incorrect. Isoprenaline (isoproterenol) is a non-selective β-adrenergic agonist that primarily stimulates both β1 and β2 receptors. It is mainly used for cardiac conditions such as bradycardia and heart block because of its potent β1 effects on the heart. Since it does not selectively act on the uterus, it is not preferred for arresting labor. (D) Terbutaline – Incorrect. Terbutaline is another β2-adrenergic agonist that is used as a tocolytic agent to relax the uterus and delay labor. However, ritodrine is preferred because it is specifically developed for this indication and has a better safety profile for tocolysis. Terbutaline is still used in some cases but is not the first choice.",
      "correct_choice_id": 229696,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/54093201700147032/54093201700147032.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/54093201700147032/54093201700147032.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54461,
      "choices": [
        {
          "id": 229698,
          "text": "Finasteride"
        },
        {
          "id": 229699,
          "text": "Terazosin"
        },
        {
          "id": 229700,
          "text": "Tamsulosin"
        },
        {
          "id": 229701,
          "text": "Amphetamine"
        }
      ],
      "text": "A drug 'X' primarily reduces the static component of urinary obstruction in benign hypertrophy of prostate and takes more than 3 months to exert its beneficial effect. Which of the following is 'X'?",
      "unique_key": "Q9027166",
      "question_audio": null,
      "question_video": null,
      "map_id": 34489184,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Finasteride. Finasteride is a 5-alpha reductase inhibitor that works by blocking the conversion of testosterone to dihydrotestosterone (DHT), the primary hormone responsible for prostate enlargement in benign prostatic hyperplasia (BPH). By reducing DHT levels, Finasteride decreases prostate volume, thereby reducing the static component of urinary obstruction. However, because prostate shrinkage is a slow process, Finasteride takes more than 3 months to show significant clinical improvement in urinary symptoms. It is particularly useful for patients with significantly enlarged prostates and helps in reducing the long-term risk of urinary retention and the need for surgery. Explanation of Incorrect Options: (B) Terazosin – Incorrect. Terazosin is an alpha-1 adrenergic blocker, which acts by relaxing smooth muscle in the bladder neck and prostate, thereby improving urine flow. However, unlike Finasteride, it does not shrink the prostate gland but rather relieves the dynamic component of urinary obstruction. It works rapidly, usually within days to weeks, making it unsuitable as the correct answer since the drug in question takes more than 3 months to exert its effect. (C) Tamsulosin – Incorrect. Similar to Terazosin, Tamsulosin is also an alpha-1 adrenergic blocker but is more selective for the alpha-1A receptors found in the prostate. It provides symptomatic relief within days by relaxing the smooth muscle of the prostate and bladder neck. However, it does not shrink prostate size or reduce the static component of BPH, making it incorrect. (D) Amphetamine – Incorrect. Amphetamines are central nervous system stimulants used primarily for conditions like ADHD and narcolepsy. They do not play any role in the treatment of BPH and have no effect on the static or dynamic components of urinary obstruction.",
      "correct_choice_id": 229698,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/30107341700147169/30107341700147169.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/30107341700147169/30107341700147169.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54462,
      "choices": [
        {
          "id": 229702,
          "text": "Enhancing GI calcium absorption"
        },
        {
          "id": 229703,
          "text": "Inhibiting calcium excretion in the kidneys"
        },
        {
          "id": 229704,
          "text": "Inhibiting osteoclasts"
        },
        {
          "id": 229705,
          "text": "Providing the starting material for bone mineralization"
        },
        {
          "id": 229706,
          "text": "Stimulating osteoblasts"
        }
      ],
      "text": "A 65-year-old woman falls at home and fractures her wrist. She has a 40 pack-year history of smoking. Her doctor recommends a DXA scan, which reveals a very low bone density and prescribes alendronate. How will alendronate help this patient?",
      "unique_key": "Q7421036",
      "question_audio": null,
      "question_video": null,
      "map_id": 34355447,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Inhibiting osteoclasts Explanation for the Correct Answer: Alendronate is a bisphosphonate, a drug that helps in the treatment and prevention of osteoporosis by inhibiting osteoclast-mediated bone resorption. Osteoclasts are responsible for breaking down bone tissue, leading to decreased bone density, especially in conditions like postmenopausal osteoporosis or osteoporosis due to smoking history (as seen in this patient). Mechanism of action of Alendronate: Binds to hydroxyapatite in bone Inhibits osteoclast function, leading to reduced bone resorption Promotes apoptosis of osteoclasts while preserving osteoblast function Increases bone mineral density (BMD) and reduces the risk of fractures Since osteoclast activity outweighs osteoblast activity in osteoporosis, inhibiting osteoclasts helps restore bone strength and prevent further fractures. Thus, the correct answer is (C) Inhibiting osteoclasts. Explanation for the Incorrect Answers: (A) Enhancing GI calcium absorption – Incorrect Calcium absorption in the intestines is regulated by Vitamin D and parathyroid hormone (PTH), not alendronate. Alendronate does not enhance calcium absorption; instead, it reduces bone breakdown to help maintain bone density. Drugs like calcitriol (active vitamin D) increase calcium absorption, but not bisphosphonates. (B) Inhibiting calcium excretion in the kidneys – Incorrect Renal calcium excretion is controlled by PTH and Vitamin D, not alendronate. Thiazide diuretics (e.g., hydrochlorothiazide) are known to reduce calcium excretion, but bisphosphonates do not affect kidney calcium handling. (D) Providing the starting material for bone mineralization – Incorrect The primary bone mineral components are calcium and phosphate. Alendronate is not a direct mineral source for bone; it only prevents bone loss by inhibiting osteoclasts. Calcium and vitamin D supplements provide the material for mineralization, but not bisphosphonates. (E) Stimulating osteoblasts – Incorrect Osteoblasts build bone, but bisphosphonates do not directly stimulate them. Teriparatide (PTH analog) stimulates osteoblasts and bone formation, unlike alendronate, which primarily prevents bone resorption.",
      "correct_choice_id": 229704,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25551241700305032/25551241700305032.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25551241700305032/25551241700305032.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54463,
      "choices": [
        {
          "id": 229707,
          "text": "Methimazole"
        },
        {
          "id": 229708,
          "text": "Bromocriptine"
        },
        {
          "id": 229709,
          "text": "Levothyroxine"
        },
        {
          "id": 229710,
          "text": "Metformin"
        }
      ],
      "text": "A 50-year-old woman presents with signs of hyperprolactinemia. Which of the following medications can be used to treat this condition?",
      "unique_key": "Q4254951",
      "question_audio": null,
      "question_video": null,
      "map_id": 34332415,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Bromocriptine. Bromocriptine is a dopamine (D2) receptor agonist that inhibits prolactin secretion from the anterior pituitary gland. Hyperprolactinemia is often caused by prolactin-secreting pituitary adenomas (prolactinomas), and excessive prolactin levels can lead to galactorrhea, amenorrhea, infertility, and hypogonadism. Dopamine naturally inhibits prolactin secretion, so drugs like bromocriptine or cabergoline (another D2 agonist) are the first-line treatment for prolactinomas and hyperprolactinemia. Explanation of Incorrect Options: (A) Methimazole – Incorrect. Methimazole is an antithyroid drug used to treat hyperthyroidism by inhibiting thyroid hormone synthesis. While hypothyroidism can cause compensatory hyperprolactinemia, methimazole does not directly treat hyperprolactinemia and is not used in its management. (C) Levothyroxine – Incorrect. Levothyroxine (T4) is used to treat hypothyroidism, which can sometimes lead to elevated prolactin levels due to increased TRH (thyrotropin-releasing hormone) stimulation of the pituitary. In cases where hypothyroidism is the underlying cause of hyperprolactinemia, levothyroxine may help, but it is not the primary treatment for prolactinomas or idiopathic hyperprolactinemia. (D) Metformin – Incorrect. Metformin is used to treat type 2 diabetes mellitus and polycystic ovary syndrome (PCOS) by improving insulin sensitivity. While PCOS is sometimes associated with mild hyperprolactinemia, metformin does not directly lower prolactin levels and is not a treatment for prolactin-secreting tumors.",
      "correct_choice_id": 229708,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54464,
      "choices": [
        {
          "id": 229711,
          "text": "Octreotide"
        },
        {
          "id": 229712,
          "text": "Pegvisomant"
        },
        {
          "id": 229713,
          "text": "Cabergoline"
        },
        {
          "id": 229714,
          "text": "Bromocriptine"
        }
      ],
      "text": "A 28-year-old man is diagnosed with acromegaly due to a growth hormone-secreting pituitary adenoma. Which of the following medications is most appropriate for initial treatment?",
      "unique_key": "Q4809774",
      "question_audio": null,
      "question_video": null,
      "map_id": 34169563,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Octreotide. Acromegaly is caused by excessive growth hormone (GH) secretion, usually due to a pituitary adenoma. The initial treatment of choice is transsphenoidal surgery, but when surgery is not possible or does not fully control GH levels, medical therapy is required. Octreotide, a somatostatin analog, is the first-line medical treatment as it inhibits GH secretion by binding to somatostatin receptors on the tumor. This leads to decreased GH and insulin-like growth factor-1 (IGF-1) levels, helping to control the disease. Explanation of Incorrect Options: (B) Pegvisomant – Incorrect. Pegvisomant is a GH receptor antagonist that blocks GH action at peripheral tissues, reducing IGF-1 levels. It is used when octreotide or surgery is ineffective, but it does not shrink the tumor or reduce GH secretion. Hence, it is not the preferred initial treatment. (C) Cabergoline – Incorrect. Cabergoline is a dopamine agonist primarily used for prolactinomas. While it can reduce GH levels in some mild cases of acromegaly, it is less effective than somatostatin analogs like octreotide and is not the first-line treatment. (D) Bromocriptine – Incorrect. Bromocriptine is also a dopamine agonist, mainly used for prolactinomas. It has limited efficacy in treating acromegaly, as most GH-secreting adenomas do not respond well to dopamine agonists.",
      "correct_choice_id": 229711,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54465,
      "choices": [
        {
          "id": 229715,
          "text": "Spironolactone"
        },
        {
          "id": 229716,
          "text": "Metyrapone"
        },
        {
          "id": 229717,
          "text": "Metformin"
        },
        {
          "id": 229718,
          "text": "Levothyroxine"
        }
      ],
      "text": "A 50-year-old female is diagnosed with Cushing’s syndrome. Which of the following medications can be used to help control cortisol production?",
      "unique_key": "Q4414915",
      "question_audio": null,
      "question_video": null,
      "map_id": 34637297,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Metyrapone. Cushing’s syndrome is caused by excessive cortisol production, usually due to an adrenal tumor, pituitary adenoma (Cushing’s disease), or ectopic ACTH production. Metyrapone is a steroidogenesis inhibitor that blocks the enzyme 11?-hydroxylase, which is required for cortisol synthesis in the adrenal glands. By inhibiting this enzyme, metyrapone reduces cortisol production, making it useful for short-term management of Cushing’s syndrome, especially in patients awaiting surgery or in cases where surgery is not an option. Explanation of Incorrect Options: (A) Spironolactone – Incorrect. Spironolactone is an aldosterone antagonist used to treat hyperaldosteronism, hypertension, and heart failure. While it helps manage hypertension and hypokalemia (common in Cushing’s syndrome), it does not directly inhibit cortisol production. (C) Metformin – Incorrect. Metformin is a biguanide used for type 2 diabetes. While Cushing’s syndrome can cause insulin resistance and diabetes, metformin only improves glucose control and does not affect cortisol levels. (D) Levothyroxine – Incorrect. Levothyroxine is a thyroid hormone replacement used to treat hypothyroidism. It has no role in cortisol regulation or the treatment of Cushing’s syndrome.",
      "correct_choice_id": 229716,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54466,
      "choices": [
        {
          "id": 229719,
          "text": "Clomiphene citrate"
        },
        {
          "id": 229720,
          "text": "Testosterone enanthate"
        },
        {
          "id": 229721,
          "text": "GnRH analogs"
        },
        {
          "id": 229722,
          "text": "Tamoxifen"
        }
      ],
      "text": "A 35-year-old man is diagnosed with secondary hypogonadism. Which of the following therapies is the most appropriate to increase testosterone levels?",
      "unique_key": "Q6623151",
      "question_audio": null,
      "question_video": null,
      "map_id": 34135060,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Testosterone enanthate. Secondary hypogonadism occurs due to impaired hypothalamic or pituitary function, leading to low testosterone levels and inadequate stimulation of the testes. Testosterone enanthate, a long-acting testosterone ester, is used as testosterone replacement therapy (TRT) to restore normal testosterone levels. It is administered via intramuscular injection and helps alleviate symptoms such as low libido, fatigue, muscle loss, and osteoporosis associated with testosterone deficiency. Explanation of Incorrect Options: (A) Clomiphene citrate – Incorrect. Clomiphene is a selective estrogen receptor modulator (SERM) that increases gonadotropin (LH and FSH) secretion, stimulating endogenous testosterone production. While it is useful in fertility treatment for men with functional hypogonadism, it is not the first-line treatment for secondary hypogonadism requiring direct testosterone replacement. (C) GnRH analogs – Incorrect. GnRH analogs (such as leuprolide) stimulate LH and FSH secretion when given in a pulsatile manner, but suppress gonadotropins when given continuously. While useful in some cases of hypogonadotropic hypogonadism, they are not the standard therapy for testosterone replacement in adults with secondary hypogonadism. (D) Tamoxifen – Incorrect. Tamoxifen is a SERM that blocks estrogen receptors in the hypothalamus and pituitary, leading to increased LH and FSH secretion. Like clomiphene, it can boost endogenous testosterone production, but it is primarily used in hormone-sensitive breast cancer and is not the preferred treatment for testosterone replacement.",
      "correct_choice_id": 229720,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54467,
      "choices": [
        {
          "id": 229723,
          "text": "Take it with a full glass of milk."
        },
        {
          "id": 229724,
          "text": "Remain upright for at least 30 minutes after taking it."
        },
        {
          "id": 229725,
          "text": "Take it at bedtime."
        },
        {
          "id": 229726,
          "text": "It can be taken with food for better absorption."
        }
      ],
      "text": "A 65-year-old woman with osteoporosis is prescribed alendronate. Which of the following instructions should she be given regarding this medication?",
      "unique_key": "Q3092265",
      "question_audio": null,
      "question_video": null,
      "map_id": 34245033,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Remain upright for at least 30 minutes after taking it. Alendronate is a bisphosphonate used to treat osteoporosis by inhibiting osteoclast-mediated bone resorption, thereby increasing bone mineral density. One of the most important administration instructions is to remain upright for at least 30 minutes after taking it. This precaution reduces the risk of esophagitis, esophageal ulcers, and reflux, which are common adverse effects if the drug irritates the esophageal mucosa. Additionally, patients should take it with a full glass of water (not milk) to aid proper absorption and minimize gastrointestinal side effects. Explanation of Incorrect Options: (A) Take it with a full glass of milk – Incorrect. Milk contains calcium, which can bind to alendronate and reduce its absorption in the gastrointestinal tract. It is recommended to take alendronate with plain water and to avoid calcium supplements or dairy products for at least 30 minutes after ingestion. (C) Take it at bedtime – Incorrect. Taking alendronate at bedtime increases the risk of esophageal irritation and reflux if the patient lies down too soon. It should be taken in the morning on an empty stomach with at least 8 oz of water to ensure proper absorption and minimize esophageal side effects. (D) It can be taken with food for better absorption – Incorrect. Food significantly reduces alendronate absorption, particularly foods high in calcium, iron, or magnesium. Patients should take alendronate on an empty stomach, at least 30 minutes before breakfast, to maximize its effectiveness.",
      "correct_choice_id": 229724,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54468,
      "choices": [
        {
          "id": 229727,
          "text": "Inhibition of growth hormone release"
        },
        {
          "id": 229728,
          "text": "Blocking growth hormone receptor signaling"
        },
        {
          "id": 229729,
          "text": "Stimulation of somatostatin receptors"
        },
        {
          "id": 229730,
          "text": "Decrease in IGF-1 production"
        }
      ],
      "text": "A patient with acromegaly is being treated with pegvisomant. What is the primary mechanism of action of this medication?",
      "unique_key": "Q3219271",
      "question_audio": null,
      "question_video": null,
      "map_id": 34898179,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Blocking growth hormone receptor signaling. Pegvisomant is a growth hormone (GH) receptor antagonist that works by blocking GH receptor signaling, preventing the downstream effects of GH. Growth hormone primarily acts on the liver to stimulate the production of insulin-like growth factor-1 (IGF-1), which mediates many of GH’s effects, including tissue growth and metabolic changes. In acromegaly, excess GH leads to excessive IGF-1 production, causing abnormal bone and soft tissue growth. By competitively binding to GH receptors in the liver, pegvisomant prevents GH-induced IGF-1 production, thereby alleviating the symptoms of acromegaly. Unlike somatostatin analogs (e.g., octreotide), pegvisomant does not reduce GH secretion from the pituitary but instead blocks its effects at the receptor level. Explanation of Incorrect Options: A. Inhibition of growth hormone release – Incorrect Pegvisomant does not directly inhibit GH release from the pituitary gland. Instead, it blocks GH receptors, preventing its downstream effects. Drugs that inhibit GH release include somatostatin analogs (e.g., octreotide, lanreotide), which work by suppressing GH secretion at the hypothalamic-pituitary level. C. Stimulation of somatostatin receptors – Incorrect Pegvisomant does not activate somatostatin receptors. Somatostatin is a hormone that inhibits GH secretion, and its synthetic analogs (e.g., octreotide, lanreotide) are used in acromegaly treatment to suppress GH production. Pegvisomant, in contrast, blocks GH action at the receptor level rather than influencing its secretion. D. Decrease in IGF-1 production – Incorrect but partially related While pegvisomant does lead to a decrease in IGF-1 levels, it achieves this effect by blocking GH receptor signaling, not by directly inhibiting IGF-1 production. IGF-1 production is stimulated by GH, so by preventing GH from acting on its receptors, pegvisomant indirectly reduces IGF-1 synthesis. However, the direct mechanism is GH receptor blockade, making option B the more precise answer.",
      "correct_choice_id": 229728,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54469,
      "choices": [
        {
          "id": 229731,
          "text": "Bisphosphonates"
        },
        {
          "id": 229732,
          "text": "Estrogen"
        },
        {
          "id": 229733,
          "text": "Calcium supplements"
        },
        {
          "id": 229734,
          "text": "Glucocorticoids"
        }
      ],
      "text": "A 70-year-old woman is being evaluated for primary hyperparathyroidism. Which of the following medications can be used to lower serum calcium levels before surgery?",
      "unique_key": "Q4025584",
      "question_audio": null,
      "question_video": null,
      "map_id": 34026165,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Bisphosphonates. Bisphosphonates (e.g., alendronate, zoledronic acid, pamidronate) are used to lower serum calcium levels in patients with primary hyperparathyroidism (PHPT), particularly in those awaiting parathyroidectomy. These drugs work by inhibiting osteoclast-mediated bone resorption, thereby reducing the release of calcium from bones into the bloodstream. In patients with symptomatic hypercalcemia, bisphosphonates are particularly useful because they provide a longer-term reduction in calcium levels compared to other treatments like IV fluids or calcitonin. They are often administered intravenously (e.g., zoledronic acid or pamidronate) for more rapid calcium-lowering effects. Explanation of Incorrect Options: B. Estrogen – Incorrect Estrogen therapy was historically used to help manage postmenopausal osteoporosis and may have a mild effect in reducing bone resorption. However, it is not the first-line treatment for hypercalcemia in primary hyperparathyroidism, especially in older patients, due to concerns about cardiovascular risks and increased risk of thromboembolism. Additionally, its calcium-lowering effects are far less potent than those of bisphosphonates. C. Calcium supplements – Incorrect Calcium supplements would increase serum calcium levels, which is the opposite of what is needed in a patient with hyperparathyroidism. While calcium supplementation may be used post-surgery if hypocalcemia occurs, it is not appropriate for acute management of hypercalcemia before surgery. D. Glucocorticoids – Incorrect Glucocorticoids (e.g., prednisone) can be used to lower calcium levels in conditions like granulomatous diseases (e.g., sarcoidosis) and vitamin D toxicity, where calcium absorption from the intestines is excessive. However, they are not effective for hypercalcemia caused by primary hyperparathyroidism, as the primary mechanism in PHPT is increased PTH-driven bone resorption, which is best countered by bisphosphonates.",
      "correct_choice_id": 229731,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54470,
      "choices": [
        {
          "id": 229735,
          "text": "Pegvisomant"
        },
        {
          "id": 229736,
          "text": "Insulin"
        },
        {
          "id": 229737,
          "text": "Desmopressin"
        },
        {
          "id": 229738,
          "text": "Levothyroxine"
        }
      ],
      "text": "Which drug may be prescribed to treat Acromegely?",
      "unique_key": "Q9458500",
      "question_audio": null,
      "question_video": null,
      "map_id": 34282475,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Pegvisomant. Pegvisomant is a growth hormone (GH) receptor antagonist used in the treatment of acromegaly, a condition caused by excessive GH secretion, usually due to a pituitary adenoma. Acromegaly leads to excess production of insulin-like growth factor-1 (IGF-1), resulting in abnormal tissue growth, enlarged hands and feet, facial changes, and metabolic disturbances. Pegvisomant works by blocking GH receptors in the liver, preventing GH from stimulating IGF-1 production. This leads to a decrease in IGF-1 levels, thereby reducing the symptoms and complications of acromegaly. Unlike somatostatin analogs (e.g., octreotide, lanreotide) or dopamine agonists (e.g., cabergoline), which reduce GH secretion, pegvisomant directly inhibits GH action at the receptor level, making it a highly effective therapy in resistant or severe cases. Explanation of Incorrect Options: B. Insulin – Incorrect While acromegaly can lead to insulin resistance and diabetes mellitus, insulin itself does not treat acromegaly. Instead, controlling GH levels with medications like pegvisomant, somatostatin analogs, or surgery helps improve insulin sensitivity. Insulin is only used for managing diabetes, which can be a secondary complication of acromegaly, not for treating the primary condition. C. Desmopressin – Incorrect Desmopressin is a synthetic vasopressin analog used to treat diabetes insipidus (DI) and von Willebrand disease. It works by increasing water reabsorption in the kidneys, reducing excessive urination in DI. However, it has no role in the treatment of acromegaly, which is caused by excess GH, not vasopressin deficiency. D. Levothyroxine – Incorrect Levothyroxine is a synthetic thyroid hormone (T4) used to treat hypothyroidism. While some patients with acromegaly may develop secondary hypothyroidism due to pituitary adenoma compression, levothyroxine does not directly treat acromegaly. The mainstay of acromegaly treatment focuses on GH suppression or receptor blockade, making levothyroxine irrelevant for this condition.",
      "correct_choice_id": 229735,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54471,
      "choices": [
        {
          "id": 229739,
          "text": "Decides to start using an oral contraceptive"
        },
        {
          "id": 229740,
          "text": "Has postmenopausal osteoporosis and is at risk for breast cancer"
        },
        {
          "id": 229741,
          "text": "Needs postcoital contraception"
        },
        {
          "id": 229742,
          "text": "Suffers from hirsutism"
        }
      ],
      "text": "Raloxifene is a selective estrogen receptor modulator (SERM). Its characteristic properties make the drug most suitable for treatment of a female patient who",
      "unique_key": "Q1747548",
      "question_audio": null,
      "question_video": null,
      "map_id": 34863025,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Has postmenopausal osteoporosis and is at risk for breast cancer. Raloxifene is a Selective Estrogen Receptor Modulator (SERM) that has tissue-specific effects on estrogen receptors. It acts as an estrogen agonist in bones but an estrogen antagonist in the breast and uterus. Because of these properties, raloxifene is used for: Prevention and treatment of postmenopausal osteoporosis – By acting as an agonist on bone estrogen receptors, raloxifene helps reduce bone resorption and increase bone mineral density (BMD), decreasing the risk of vertebral fractures. Reduction of breast cancer risk – Raloxifene functions as an estrogen antagonist in breast tissue, blocking estrogen’s proliferative effects, which helps reduce the risk of estrogen receptor-positive (ER+) breast cancer. It is often preferred in postmenopausal women who are at high risk of developing breast cancer. Unlike traditional hormone replacement therapy (HRT), raloxifene does not stimulate the endometrium, so it does not increase the risk of endometrial hyperplasia or cancer. This makes it a safer alternative to estrogen therapy for osteoporosis treatment in postmenopausal women. Explanation of Incorrect Options: A. Decides to start using an oral contraceptive – Incorrect Raloxifene is not used for contraception. Oral contraceptives typically contain estrogen and progestin, which work by suppressing ovulation and altering cervical mucus to prevent pregnancy. Raloxifene, on the other hand, does not inhibit ovulation and is not effective as a contraceptive method. C. Needs postcoital contraception – Incorrect Postcoital (emergency) contraception involves high-dose progestins (levonorgestrel) or antiprogestins (ulipristal, mifepristone) to prevent ovulation and implantation. Raloxifene does not have any effect on the ovarian cycle or implantation, making it ineffective as a postcoital contraceptive. D. Suffers from hirsutism – Incorrect Hirsutism (excessive hair growth in a male-pattern distribution) is often due to androgen excess, such as in polycystic ovary syndrome (PCOS). The treatment typically involves oral contraceptives, anti-androgens (spironolactone, finasteride), or GnRH agonists. Raloxifene has no significant anti-androgenic activity and does not address the underlying cause of hirsutism.",
      "correct_choice_id": 229740,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54472,
      "choices": [
        {
          "id": 229743,
          "text": "Osteoporosis"
        },
        {
          "id": 229744,
          "text": "Hypercalcemia"
        },
        {
          "id": 229745,
          "text": "With anti cancers"
        },
        {
          "id": 229746,
          "text": "Tetany"
        }
      ],
      "text": "Bisphosphonates are used in all except",
      "unique_key": "Q4033798",
      "question_audio": null,
      "question_video": null,
      "map_id": 34872142,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Tetany. Bisphosphonates are drugs that inhibit bone resorption by acting on osteoclasts, reducing bone turnover and lowering serum calcium levels. They are widely used for conditions associated with excess bone resorption or hypercalcemia. However, they are not used to treat tetany, which is caused by low calcium levels (hypocalcemia). Tetany results from hypoparathyroidism, severe vitamin D deficiency, or acute hypocalcemia, and its treatment requires calcium supplementation and vitamin D, not bisphosphonates, which would further decrease calcium levels. Explanation of Incorrect Options: A. Osteoporosis – Incorrect Bisphosphonates (e.g., alendronate, risedronate, zoledronic acid) are first-line therapy for osteoporosis. They work by inhibiting osteoclast-mediated bone resorption, increasing bone mineral density (BMD) and reducing the risk of vertebral, hip, and other fractures. B. Hypercalcemia – Incorrect Bisphosphonates are commonly used to treat hypercalcemia of malignancy, as they reduce serum calcium levels by preventing excessive bone breakdown. They are particularly effective in conditions like primary hyperparathyroidism, multiple myeloma, and metastatic bone disease, where hypercalcemia is a common complication. C. With anti-cancers – Incorrect Bisphosphonates are used in conjunction with anticancer therapies to prevent bone complications in cancers that metastasize to bone, such as breast cancer, prostate cancer, and multiple myeloma. They help in reducing skeletal-related events (SREs), bone pain, and pathological fractures. Zoledronic acid and pamidronate are commonly used in oncology settings.",
      "correct_choice_id": 229746,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54473,
      "choices": [
        {
          "id": 229747,
          "text": "Alendronate"
        },
        {
          "id": 229748,
          "text": "Raloxifene"
        },
        {
          "id": 229749,
          "text": "Teriparatide"
        },
        {
          "id": 229750,
          "text": "Strontium"
        }
      ],
      "text": "All are anti resorptive drugs for bone growth except?",
      "unique_key": "Q8867951",
      "question_audio": null,
      "question_video": null,
      "map_id": 34102604,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Teriparatide. Teriparatide is not an anti-resorptive drug; instead, it is an anabolic (bone-forming) agent. It is a recombinant form of parathyroid hormone (PTH 1-34) that stimulates osteoblast activity, leading to new bone formation. Unlike anti-resorptive drugs that work by inhibiting bone breakdown, teriparatide increases bone mass and strength by promoting bone formation. It is primarily used in severe osteoporosis (especially in patients at high risk for fractures) and is given as a daily subcutaneous injection. Explanation of Incorrect Options: A. Alendronate – Incorrect Alendronate is a bisphosphonate, which is a classic anti-resorptive drug. It works by inhibiting osteoclast activity, reducing bone breakdown and loss, thereby preserving bone mineral density (BMD). It is commonly used for osteoporosis, Paget’s disease, and hypercalcemia of malignancy. B. Raloxifene – Incorrect Raloxifene is a Selective Estrogen Receptor Modulator (SERM) that acts as an estrogen agonist in bones and an estrogen antagonist in the breast and uterus. By mimicking estrogen’s protective effects on bone, it reduces osteoclast-mediated bone resorption, making it an effective anti-resorptive drug for postmenopausal osteoporosis. D. Strontium – Incorrect Strontium (particularly strontium ranelate) has dual action: it inhibits bone resorption (acting as an anti-resorptive agent) and stimulates bone formation. It reduces osteoclast activity while increasing osteoblast activity, making it useful in osteoporosis treatment.",
      "correct_choice_id": 229749,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    }
  ]
}